Yap B S, Plager C, Benjamin R S, Murphy W K, Legha S S, Bodey G P
Cancer Treat Rep. 1981 Mar-Apr;65(3-4):341-3.
AMSA an acridine derivative, was administered to 35 adults with previously treated advanced sarcomas. Patients with adequate bone marrow reserve received 120-150 mg/m2 of AMSA as a single dose repeated every 3 weeks. Patients with inadequate bone marrow reserve received 100-120 mg/m2 of AMSA. Among 31 evaluable patients, there was one partial response that lasted 6 months in a patient with intra-abdominal malignant fibrous histiocytoma with liver metastases. Thirteen patients had stable disease with a median time to disease progression of 5 months (range, 2-13), while 17 patients demonstrated progressive disease with a median time to disease progression of 2 months (range, 1-3). The median survival time for the 31 evaluable patients in this study was 5 months. The toxic effects were mild and included myelosuppression, nausea and vomiting, fever of unknown origin, and fatigue. At the dose and schedule used in this study, AMSA does not appear to have any significant activity in advanced sarcomas of adults.
吖啶衍生物氨茴霉素（AMSA）用于治疗35例先前接受过治疗的晚期肉瘤成年患者。骨髓储备充足的患者接受120 - 150mg/m²的AMSA单剂量治疗，每3周重复一次。骨髓储备不足的患者接受100 - 120mg/m²的AMSA。在31例可评估患者中，1例患有伴有肝转移的腹腔内恶性纤维组织细胞瘤的患者出现了持续6个月的部分缓解。13例患者病情稳定，疾病进展的中位时间为5个月（范围2 - 13个月），而17例患者病情进展，疾病进展的中位时间为2个月（范围1 - 3个月）。本研究中31例可评估患者的中位生存时间为5个月。毒性作用较轻，包括骨髓抑制、恶心和呕吐、不明原因发热以及疲劳。在本研究使用的剂量和给药方案下，AMSA在成人晚期肉瘤中似乎没有任何显著活性。
